false 0001801777 NASDAQ DE 0001801777 2023-10-23 2023-10-23 0001801777 dei:BusinessContactMember 2023-10-23 2023-10-23

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 23, 2023

 

 

APPLIED MOLECULAR TRANSPORT INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39306   81-4481426

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

Address not Applicable(1)

(Address of principal executive offices, including zip code)

(650) 392-0420

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol

 

Name of exchange

on which registered

Common Stock, par value $0.0001 per share   AMTI   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

1 

We are a remote-only company. Accordingly, we do not maintain a headquarters. For purposes of compliance with applicable requirements of the Securities Act of 1933, as amended, or the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, any stockholder communication required to be sent to our principal executive offices may be directed to the agent for service of process at the following address: Applied Molecular Transport Inc., c/o The Corporation Trust Company, Corporation Trust Center, 1209 Orange Street, Wilmington, DE 19801, or to the email address: corporate.secretary@appliedmt.com.

 

 

 


Item 8.01 Other Events.

On October 23, 2023, Applied Molecular Transport Inc. (the “Company”) received written notice from the Nasdaq Hearings Panel (the “Nasdaq Panel”) that the Nasdaq Panel had granted the Company’s request for continued listing on The Nasdaq Stock Market LLC (“Nasdaq”), subject to the Company’s completion of its business combination with Cyclo Therapeutics, Inc. on or before February 6, 2024.

As previously disclosed, on August 10, 2023, the Company received a letter from Nasdaq’s Listing Qualifications Staff (“Nasdaq Staff”) indicating that, in accordance with Nasdaq Listing Rule 5100, the Nasdaq Staff believed the Company to be a “public shell” and, therefore, the continued listing of the Company’s securities was no longer warranted. The Company thereafter requested a hearing before the Nasdaq Panel, which request stayed any further action by Nasdaq Staff with respect to the Company’s listing pending a determination by the Nasdaq Panel. The hearing was held on October 19, 2023.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    APPLIED MOLECULAR TRANSPORT INC.
Date: October 25, 2023     By:  

/s/ Shawn Cross

      Shawn Cross
      Chief Executive Officer and Chair of the Board of Directors
v3.23.3
Document and Entity Information
Oct. 23, 2023
Entity Addresses [Line Items]  
Document Type 8-K
Document Period End Date Oct. 23, 2023
Entity Registrant Name APPLIED MOLECULAR TRANSPORT INC.
Entity Incorporation State Country Code DE
Entity File Number 001-39306
Entity Tax Identification Number 81-4481426
City Area Code 650
Local Phone Number 392-0420
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol AMTI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001801777
Business Contact [Member]  
Entity Addresses [Line Items]  
Entity Address Address Line 1 1209 Orange Street
Entity Address City Or Town Wilmington
Entity Address State Or Province DE
Entity Address Postal Zip Code 19801

Applied Molecular Transp... (NASDAQ:AMTI)
Historical Stock Chart
From Jan 2024 to Feb 2024 Click Here for more Applied Molecular Transp... Charts.
Applied Molecular Transp... (NASDAQ:AMTI)
Historical Stock Chart
From Feb 2023 to Feb 2024 Click Here for more Applied Molecular Transp... Charts.